Home Membership Newsletter Forthcoming Events Articles
Articles
Disability In India
Spinal Cord Injuries In India
ScI – Why So Different?
Sexuality In Spinal Cord Injury
Spinal Cord Injury – The Solutions Of The Future
ITB Therapy
Intrathecal Drug Delivery System (Synchromed-II)
 
  



 
Spinal Cord Injury - The Solutions of the Future
Till the early part of the last century, cases of Spinal Cord Injuries invariably ended fatally within a few weeks of the injury, if not at the time of trauma itself. A radical change in the approach to a patient with SCI occurred soon after the Second World War. The surgical techniques were developed during the 1950s and 60s. The last two decades brought in significant advancements in Spinal Injury Management including methlyprednisolone and GM1 therapy, intracthecal baclofen pump, titanium cage for vertebral repair, delayed decompression for restoring function, ileal conduits, stents and artificial sphincters for bladder and bowel, sacral anterior root stimulator, tendon transfers to restore hand grasp strength, etc. It also brought in promising therapies like IN-1 antibody stimulating regeneration drugs like 4 AP improving in people with chronic spinal injury and neurotrophin-secreting fibroblast transplants. Today, a spinal surgeon has a significant armamentarium with which to tackle the problem of SCI.

The future of SCI Management lies in-
  • Regenerative therapies like axonal growth inhibitor blockade (Anti-Nogo antibody IN-1, Nogo receptor blockers, chondrointinase), purine nucleotides (inosine, AIT-082), therapeutic vaccines (spinal cord homogenate vaccine), cell transplants (activated macrophages, fetal stem cell transplants, olfactory ensheathing glia), electrical stimulation, PD4 inhibitors (rollipram), neurotrophins (NGF+BDNF+NT3).
  • Remyelinative Therapies like schwann cell transplants, oligodendroglial cell transplants, stem transplants (mouse, porcine & human fetal), Olfactory unsheathing glial transplants, Antibody therapies.

The current clinical trials are in the field of fetal cell transplants, 4AP, activated macrophage transplants, porcine neural stem cell transplants, alternation current electrical stimulation, AIT-082, Peripheral nerve bridge, fetal stem cell and fetal stem cell olfactory ensheathing glial transplants.

Other promising therapies are in the filed of bio-feed back train W, supported treadmill ambulation training, peripheral nerve bridges of transected cords, spinal cord stimulator to activate central pattern generators and experimental surgery (untethring, peripheral nerve transplants, omentum transplant, hyperbaric oxygen and shark embryonic transplants.

Each therapy has a limited probability of success. Multiple concurrent clinical trials are likely to achieve some break through sooner or later.

Dr. H.S. Chhabra,
Addl. Medical Director, ISIC